

01997.020000.5

PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	:	Examiner: Not Yet Assigned
SEISHI KATO ET AL.	)	
	:	Group Art Unit: 1642
Application No.: 10/633,035	)	
	:	
Filed: August 4, 2003	)	
	:	
For: HUMAN GELECTIN-9-LIKE	)	
PROTEINS AND cDNAs	:	
ENCODING THESE PROTEINS	)	February 4, 2004

Commissioner for Patents  
P. O. Box 1450  
Alexandria, Virginia 22313-1450

REQUEST FOR ISSUANCE OF CORRECTED FILING RECEIPT

Sir:


Applicants' attorneys have received an official Filing Receipt in the above-referenced application which incorrectly identifies the residential address of inventor Kouju Kamata. The address is incorrectly listed as "Kanagawa, Japan". The correct address is --Sagamihara-shi, Japan--

Additionally, the address for assignee Sagami Chemical Research Center is incorrectly listed as "Kanagawa, Japan". It also should be corrected to --Sagamihara-shi, Japan--.

Issuance of a corrected Filing Receipt with the correct addresses is accordingly respectfully requested.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should be directed to our below listed address.

Respectfully submitted,




Lawrence S. Perry  
Attorney for Applicants

Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

NY MAIN 404467v1



UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/633,035	08/04/2003	1642	1030	01997.020000.5	4	5	2

5514  
FITZPATRICK CELLA HARPER & SCINTO  
30 ROCKEFELLER PLAZA  
NEW YORK, NY 10112

LSF

CONFIRMATION NO. 5567

**FILING RECEIPT**



\*OC000000011592941\*

Date Mailed: 12/31/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

**Applicant(s)**

Seishi Kato, Sagamihara-shi, JAPAN;  
Tomoko Kimura, Kawasaki-shi, JAPAN;  
Shingo Sekine, Ageo-shi, JAPAN;  
Kouju Kamata, Kanagawa, JAPAN;

--Sagamihara-shi--

**Assignment For Published Patent Application**

Sagami Chemical Research Center, Kanagawa, JAPAN;  
Protegene Inc., Meguro-ku, JAPAN;

--Sagamihara-shi--

**Domestic Priority data as claimed by applicant**

This application is a CON of 09/485,951 02/17/2000 ABN  
which is a 371 of PCT/JP98/03670 08/19/1998

**Foreign Applications**

JAPAN 9-226468 08/22/1997

If Required, Foreign Filing License Granted: 12/31/2003

Projected Publication Date: 04/08/2004

Non-Publication Request: No

Early Publication Request: No

**Title**

Human galectin-9-like proteins and cDNAs encoding these proteins

**Preliminary Class**

536

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).